Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: How The Pandemic Impact On Pharma’s Value Chain Is Mutating

Emerging Challenges Threaten Manufacturing, Supply And Regulatory Decision-Making

Executive Summary

From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.

You may also be interested in...



Stock Watch: The Great Post-Pandemic Pharmaceutical Marketing Debate

Virtual marketing was the logical way to interact with healthcare professionals during the pandemic. It may stay after the pandemic but could be an additional expense.

Coronavirus Update: Two Treatments Progress As Moderna/Takeda Investigation Concludes

Takeda and Moderna have identified the source of metallic particles in some lots of mRNA-1273 in Japan, but believe the two deaths identified to be coincidental. Pfizer starts protease inhibitor trial, and Rigel reports fostamatinib data. 

Stock Watch: Protocol Changes Preface Poor Trial Outcomes

It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel